远程缺血预适应预防静脉注射对比剂后对比剂肾病的效果:一项随机对照试验
这项前瞻性、随机、单盲、对照试验纳入26例Mehran风险评分≥6、因评估经导管主动脉瓣植入可行性而接受增强CT的住院患者,比较远程缺血预适应(RIPC)组与对照组对比剂肾病(CIN)发生率。对照组发生1例CIN,RIPC组无CIN发生(p=0.48,分析25例)。作者认为静脉注射对比剂后CIN风险很低,Mehran风险评分可能不适用于评估静脉注射对比剂后的CIN风险。
要点
- Mehran风险评分≥6的患者静脉注射对比剂后CIN发生率很低,对照组仅1例、RIPC组0例。
- 两组各时点血肌酐和胱抑素C水平变化均无统计学显著差异。
- 作者认为Mehran风险评分可能不适用于评估静脉注射对比剂后的CIN风险。
核心结论
- 静脉注射对比剂后CIN风险很低,即使在Mehran风险评分≥6且无法接受预防性水化的患者中也是如此。
- 因此,Mehran风险评分可能不是评估静脉注射对比剂后CIN风险的合适方法。
研究设计与样本
- 前瞻性、随机、单盲、对照试验,纳入26例因评估经导管主动脉瓣植入可行性而住院并接受增强CT检查、Mehran风险评分≥6的患者。
- RIPC组13例,袖带充气至患者收缩压以上50 mm Hg;对照组13例,袖带充气至患者收缩压以下10 mm Hg。
- 所有患者均接受4个循环的5分钟袖带充气后完全放气5分钟。
- 主要终点为CIN发生,同时评估血清胱抑素C水平变化。
诊断标准与关键数值
- 主要终点CIN:对照组1例,RIPC组0例(p=0.48,分析25例患者)。
- RIPC组基线、注射对比剂后24小时、48小时平均肌酐分别为88±32 μmol/L、91±28 μmol/L、82±29 μmol/L(p=0.73)。
- 对照组基线、注射对比剂后24小时、48小时平均肌酐分别为100±36 μmol/L、110±36 μmol/L、105±34 μmol/L(p=0.78)。
- RIPC组基线、24小时、48小时胱抑素C中位数[Q1, Q3]分别为1.10 [1.08, 1.18] mg/L、1.17 [0.97, 1.35] mg/L、1.12 [0.99, 1.24] mg/L(p=0.88)。
- 对照组基线、24小时、48小时胱抑素C中位数[Q1, Q3]分别为1.11 [0.97, 1.28] mg/L、1.13 [1.08, 1.25] mg/L、1.16 [1.03, 1.31] mg/L(p=0.93)。
临床应用与阅片要点
- 作者认为,静脉注射对比剂后CIN风险很低,Mehran风险评分可能不适用于评估静脉注射对比剂后的CIN风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: We aimed to assess the effects of remote ischemic pre-conditioning (RIPC) on the incidence of contrast-induced nephropathy (CIN) after an intravenous (IV) or intra-arterial injection of contrast medium (CM) in patient and control groups.
MATERIALS AND METHODS: This prospective, randomized, single-blinded, controlled trial included 26 patients who were hospitalized for the evaluation of the feasibility of transcatheter aortic valve implantation and underwent investigations including contrast-enhanced computed tomography (CT), with Mehran risk scores greater than or equal to six. All the patients underwent four cycles of five minute-blood pressure cuff inflation followed by five minutes of total deflation. In the RIPC group (n = 13), the cuff was inflated to 50 mm Hg above the patient's systolic blood pressure (SBP); in the control group (n = 13), it was inflated to 10 mm Hg below the patient's SBP. The primary endpoint was the occurrence of CIN. Additionally, variation in the serum levels of cystatin C was assessed.
RESULTS: One case of CIN was observed in the control group, whereas no cases were detected in the RIPC group (p = 0.48, analysis of 25 patients). Mean creatinine values at the baseline, 24 hours after injection of CM, and 48 hours after injection of CM were 88 ± 32 μmol/L, 91 ± 28 μmol/L and 82 ± 29 μmol/L, respectively (p = 0.73) in the RIPC group, whereas in the control group, they were 100 ± 36 μmol/L, 110 ± 36 μmol/L, and 105 ± 34 μmol/L, respectively (p = 0.78). Cystatin C values (median [Q1, Q3]) at the baseline, 24 hours after injection of CM, and 48 hours after injection of CM were 1.10 [1.08, 1.18] mg/L, 1.17 [0.97, 1.35] mg/L, and 1.12 [0.99, 1.24] mg/L, respectively (p = 0.88) in the RIPC group, whereas they were 1.11 [0.97, 1.28] mg/L, 1.13 [1.08, 1.25] mg/L, and 1.16 [1.03, 1.31] mg/L, respectively (p = 0.93), in the control group.
CONCLUSION: The risk of CIN after an IV injection of CM is very low in patients with Mehran risk score greater than or equal to six and even in the patients who are unable to receive preventive hyperhydration. Hence, the Mehran risk score may not be an appropriate method for the estimation of the risk of CIN after IV CM injection.
引用
- Belabbas D, Koch C, Chaudru S, et al. Effects of Remote Ischemic Pre-Conditioning to Prevent Contrast-Induced Nephropathy after Intravenous Contrast Medium Injection: A Randomized Controlled Trial. Korean J Radiol. 2020. PMID: 32729273. doi:10.3348/kjr.2019.0916
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。